Spots Global Cancer Trial Database for Phase I/II Combination With Irinotecan- Erbitux
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I/II Combination With Irinotecan- Erbitux
Official Title: A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs Placebo in Combination With Erbitux and Irinotecan K-Ras Wildtype Subjects With Metastatic Colorectal Cancer
Study ID: NCT00594984
Conditions
Study Description
Brief Summary: Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median duration of progression free survival (PFS)
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Usc/Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
James Graham Brown Cancer Center, Louisville, Kentucky, United States
Washington University, Saint Louis, Missouri, United States
Local Institution, Buenos Aires, , Argentina
Local Institution, Odense C, , Denmark
Local Institution, Meldola Fc, , Italy
Local Institution, Milano, , Italy
Local Institution, Seoul, , Korea, Republic of
Local Institution, Madrid, , Spain
Local Institution, Stockholm, , Sweden
Local Institution, Uppsala, , Sweden
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
